HYDROCHLOROTHIAZIDE; LISINOPRIL - Generic Drug Details

What are the generic sources for hydrochlorothiazide; lisinopril and what is the scope of freedom to operate?

Hydrochlorothiazide; lisinopril is the generic ingredient in three branded drugs marketed by Aiping Pharm Inc, Aurobindo, Chartwell Rx, Corepharma, Epic Pharma Llc, Hikma Intl Pharms, Invagen Pharms, Lupin, Pharmobedient, Prinston Inc, Sun Pharm Inds Ltd, Teva, Watson Labs, Merck, and Almatica, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

Twenty-eight suppliers are listed for this compound.

Summary for HYDROCHLOROTHIAZIDE; LISINOPRIL

US Patents:	0
Tradenames:	3
Applicants:	15
NDAs:	15
Finished Product Suppliers / Packagers:	28
Clinical Trials:	12
DailyMed Link:	HYDROCHLOROTHIAZIDE; LISINOPRIL at DailyMed

Recent Clinical Trials for HYDROCHLOROTHIAZIDE; LISINOPRIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Texas Health Science Center, Houston	Phase 4
IPCA Laboratories Ltd.	Phase 1
Scripps Translational Science Institute	N/A

See all HYDROCHLOROTHIAZIDE; LISINOPRIL clinical trials

Pharmacology for HYDROCHLOROTHIAZIDE; LISINOPRIL

Drug Class	Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Increased Diuresis

Anatomical Therapeutic Chemical (ATC) Classes for HYDROCHLOROTHIAZIDE; LISINOPRIL

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C09AA	ACE inhibitors, plain
C09A	ACE INHIBITORS, PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE; LISINOPRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-002	Jul 20, 1989	AB	RX	Yes	No
Invagen Pharms	LISINOPRIL AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	204058-003	May 23, 2017	AB	RX	No	Yes
Hikma Intl Pharms	LISINOPRIL AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	076265-002	Jul 8, 2002		DISCN	No	No

Expired US Patents for HYDROCHLOROTHIAZIDE; LISINOPRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-002	Jul 20, 1989
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-003	Nov 18, 1993
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-001	Sep 20, 1990

Market Dynamics and Financial Trajectory for Hydrochlorothiazide and Lisinopril

Last updated: February 14, 2026

---

What is the global market outlook for hydrochlorothiazide and lisinopril?

The combined market for hydrochlorothiazide (HCTZ) and lisinopril is primarily driven by the prevalence of hypertension and heart failure. As of 2022, the global antihypertensive drug market was valued at approximately $29 billion, expected to reach $45 billion by 2030, at a compound annual growth rate (CAGR) of 5.2% (CAGR sourced from research reports).

Hydrochlorothiazide remains one of the most prescribed generic diuretics, while lisinopril is among the leading ACE inhibitors globally. Both drugs constitute significant portions of their respective markets due to their established efficacy, safety profiles, and low cost.

How do market trends influence sales and market share?

Key factors impacting sales:

• Patent expirations: Both drugs went off patent in many regions by the late 2000s and early 2010s, increasing generic drug penetration.
• Generic competition: Entry of multiple generic manufacturers has driven prices down but increased volume sales.
• Prescribing habits: Clinical guidelines favor combination therapy but also favor newer agents for resistant cases, slightly decreasing reliance on HCTZ and lisinopril.
• Regulatory approvals: Several countries have approved fixed-dose combination formulations, bolstering sales.
• Pricing and reimbursement policies: Price sensitivity and insurance coverage impact purchase volumes widely, especially in developing markets.

Market share estimation (2022):

Drug	Global sales (USD billions)	Market share in antihypertensive segment
Hydrochlorothiazide	$2.1	7.2%
Lisinopril	$2.5	8.6%

Source: IQVIA Data, 2022.

What are the primary sources of revenue and revenue trends?

Revenue comes from both generic and branded formulations, with generics dominating the market post-patent expiry. In 2022, global sales of hydrochlorothiazide are stable, mainly in the form of low-cost bulk generics, but growth is limited by commoditization. Lisinopril sales are slightly higher, also primarily generics, with incremental revenues from combination products.

Revenues over recent years:

Year	Hydrochlorothiazide (USD billions)	Lisinopril (USD billions)
2018	1.8	2.2
2019	1.9	2.3
2020	2.0	2.4
2021	2.1	2.5
2022	2.1	2.5

Growth remains flat at low single digits, reflective of market saturation and entrenched generic competition.

How do recent patent and regulatory changes impact the market?

Most patents for original formulations expired by 2010-2013. Recent regulatory initiatives have encouraged approval of generic biosimilars and fixed-dose combinations. The U.S. FDA approved several lisinopril combination products in the last five years. The declining patent protections constrict revenue growth unless offset by market expansion or new formulations.

What are future market drivers and risks?

Drivers:

• Increasing hypertension prevalence globally, particularly in developing countries.
• Expansion of fixed-dose combinations, improving adherence.
• Healthcare initiatives favoring cost-effective therapies.

Risks:

• Market saturation leading to price pressure.
• Shift toward newer agents with better safety profiles, like ARBs.
• Regulatory hurdles in emerging markets.

What is the financial outlook for manufacturers?

The outlook indicates limited revenue growth for existing formulations. Margins are under pressure in mature markets. Companies relying heavily on these drugs may see revenues plateau unless they innovate or diversify.

---

Key Takeaways

• The worldwide market for hydrochlorothiazide and lisinopril largely depends on generic sales, with limited growth potential.
• Patent expirations and generic competition keep prices low but ensure stable volume sales.
• Emerging markets offer growth opportunities, driven by increasing hypertension rates.
• Fixed-dose combinations may provide incremental growth but face regulatory and formulary barriers.
• Innovation in delivery methods or new therapeutic classes pose significant future risks to current market shares.

---

FAQs

1. How do patent expirations affect the market for hydrochlorothiazide and lisinopril?

Patent expirations led to a surge in generic formulations, reducing prices but maintaining sales volume. This results in declining revenues for brand-name manufacturers but increases accessibility and volume for generic producers.

2. Are there new formulations or combinations expected to impact the market?

Yes. Fixed-dose combinations with other antihypertensive agents are increasingly approved, aiming to improve patient adherence and broaden market share. Such formulations could generate modest revenue increases, but regulatory hurdles and market penetration limits exist.

3. How does the clinical positioning of these drugs influence market stability?

Both drugs are first-line therapies for hypertension, ensuring a consistent demand. However, newer classes like angiotensin receptor blockers (ARBs) show favorable tolerability, threatening long-term dominance.

4. What regional factors influence sales?

In developing nations, low-cost generic versions sustain volume. Regulatory frameworks and reimbursement policies significantly impact sales in mature markets like the US and EU, where cost containment policies prevail.

5. What are the future prospects for these drugs amidst the introduction of new antihypertensives?

The drugs likely will remain foundational, especially in resource-limited settings. However, in developed markets, their growth will be limited unless they are part of combination therapies tailored for resistant hypertension or specific patient populations.

---

References

[1] IQVIA, “Global Market Data Reports,” 2022.

[2] GlobalData, “Antihypertensive Drugs Market Analysis,” 2022.

[3] US Food and Drug Administration, “Drug Approvals and Labeling,” 2021.